Drug Trial Radar · NCT00122382
Remission and Joint Damage Progression in Early Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Nov 16, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,052
Actual
Start
Jul 2005
Primary completion
Feb 2008
Study completion Feb 2009
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a world wide study to evaluate the remission and joint damage in subjects treated with abatacept in addition to methotrexate versus subjects who receive methotrexate along with a placebo.
Conditions
- Rheumatoid Arthritis
Interventions
AbataceptDrug
abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months
placeboDrug
placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months
methotrexateDrug
Oral, titrated to at least 15 mg per week not to exceed 20 mg per week administered every 28 days from Month 12 to Month 24
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12Time frame: Month 12
- Mean Change From Baseline in Radiographic Total Score to Month 12Time frame: Baseline, Month 12
- Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to AEs During the Open-Label PeriodTime frame: Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
- Number of Participants With Serious Adverse Events Reported During the Open-Label PeriodTime frame: Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
- Number of Participants With SAEs With an Outcome of Death During the Open-label PeriodTime frame: Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
- Incidence Rates of Autoimmune Disorders in ABA-Treated ParticipantsTime frame: Double Blind Period (+56 days post last dose in double-blind period or start of open-label period, whichever came first). Open-label period (56 days post last dose in the open-label period or start of maintenance sub-study, whichever came first).
- Incidence Rates of Infections and Infestations of Adverse Events in ABA-Treated ParticipantsTime frame: Double Blind Period (+56 days post last dose in double-blind period or start of the open-label period, whichever came first). Open-label period (56 days post last dose in open-label period or start of maintenance sub-study, whichever came first).
- Incidence Rates of Malignant Neoplasm Adverse Events in ABA-Treated ParticipantsTime frame: Double Blind Period (+56 days post last dose in double-blind period or start of the open-label period, whichever came first). Open-label period (56 days post last dose in open-label period or start of maintenance sub-study, whichever came first).
- Number of Participants With a Serious Acute-Infusional AE of Anaphylactic Shock During Open-Label PeriodTime frame: Open-Label Period (Month 12 to Month 24)
- Number of Participants With Select Blood Chemistry Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label PeriodTime frame: Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
- Number of Participants With Hematology Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label PeriodTime frame: Continuously from start of open-label period up to 56 days post the last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
Locations
89 sites in 18 countries. Site status is shown where the registry gives one.
Rheumatology Associates Of North Alabama
Huntsville, Alabama
Talbert Medical Group
Huntington Beach, California
Arthritis Assoc And Osteo Ctr Of Col Sprgs
Colorado Springs, Colorado
New England Research Associates, Llc
Trumbull, Connecticut
Diagnostic Rheumatology And Research
Indianapolis, Indiana
Osteoporosis And Clinical Trials Center
Cumberland, Maryland
Malamet & Klein, Md, Pa
Hagerstown, Maryland
Arthritis Center Of Nebraska
Lincoln, Nebraska
Regional Rheumatology Associates
Binghamton, New York
Carolina Bone & Joint
Charlotte, North Carolina
Physicians East, Pa
Greenville, North Carolina
Carolina Pharmaceutical Research
Statesville, North Carolina
Lion Research
Norman, Oklahoma
Health Research Of Oklahoma
Oklahoma City, Oklahoma
Lynn Health Sciences Institute
Oklahoma City, Oklahoma
Altoona Center For Clinical Research
Duncansville, Pennsylvania
Low Country Research Center
Charleston, South Carolina
Walter F Chase Md Pa
Austin, Texas
Arthritis Clinic Of Northern Virginia, P.C.
Arlington, Virginia
Local Institution
Malvern, Victoria, Australia
Local Institution
Shenton Park, Western Australia, Australia
Local Institution
Antwerp, Belgium
Local Institution
Brussels, Belgium
Local Institution
Brussels, Belgium
Local Institution
Hasselt, Belgium
Local Institution
Leuven, Belgium
Local Institution
Goiânia, Goiás, Brazil
Local Institution
Curitiba, Paraná, Brazil
Local Institution
Rio de Janeiro - Rj, Rio de Janeiro, Brazil
Local Institution
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution
São Paulo, São Paulo, Brazil
Local Institution
São Paulo, São Paulo, Brazil
Local Institution
St. John's, Newfoundland and Labrador, Canada
Local Institution
Kitchener, Ontario, Canada
Local Institution
Toronto, Ontario, Canada
Local Institution
Montreal, Quebec, Canada
Local Institution
Québec, Quebec, Canada
Local Institution
Sherbrooke, Quebec, Canada
Local Institution
Saskatoon, Saskatchewan, Canada
Local Institution
Prague, Czechia
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.